For example, Ramirez et al. [56] demonstrated that glucagon-like peptide-1 (GLP-1) enhancer, sitagliptin, enhanced diastolic function and cardiac efficiency in type 2 diabetic rats by shifting fatty acid to glucose utilization in cardiomyocytes and reducing lipolysis. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.